EGFR and non-small cell lung carcinoma: EGFR TKIs have also been evaluated as induction therapy in patients with amolecularly-selected population of patients with potentially-resectable NSCLC,demonstrating good tolerability and safety but uneven results in terms ofobjective response rate (ORR) and survival [102,103].